<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127624">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01440764</url>
  </required_header>
  <id_info>
    <org_study_id>2011-P-000027/1</org_study_id>
    <secondary_id>R01NR012009</secondary_id>
    <nct_id>NCT01440764</nct_id>
  </id_info>
  <brief_title>Aerosol Inhalation Treatment for Dyspnea</brief_title>
  <official_title>Aerosol Inhalation Treatment for Dyspnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Nursing Research (NINR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this protocol is to develop and test optimal delivery of aerosol furosemide,
      a treatment that has the potential to significantly improve symptom management and enhance
      the quality of care for patients with intractable dyspnea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is study of aerosol treatment in a laboratory model of dyspnea in healthy subjects.
      This study is the first in a series of studies that will include investigation of a second
      dose in the laboratory and investigation of the treatment effect in hospitalized patients
      with refractory dyspnea. The outcome of this first study will determine the details of
      protocol for the succeeding studies.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject rating of Breathing Discomfort (dyspnea)</measure>
    <time_frame>repeated measurement for 2 hours from intervention</time_frame>
    <description>Subjects will rate breathing discomfort (dyspnea) using a visual analog scale before and after intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Multidimensional Dyspnea Profile</measure>
    <time_frame>repeated for 2 hours after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine output</measure>
    <time_frame>repeated measures for 2 hours after intervention</time_frame>
    <description>diuresis is an expected effect of furosemide. to the extent that aerosol furosemide is absorbed into the blood, diuresis is an expected 'side effect' of this treatment</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Healthy</condition>
  <condition>Dyspnea</condition>
  <arm_group>
    <arm_group_label>Aerosol Furosemide (40 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aerosol Furosemide 40mg in 4ml saline by inhalation for 5-10 minutes on 1 test day.
To be compared to Aerosol Saline (4ml) Arm and IV Furosemide Arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aerosol Furosemide (80mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aerosol Furosemide 80mg in 8ml saline by inhalation for 5-10 minutes on 1 test day.
To be compared to Aerosol Saline (8ml) Arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aerosol Saline (4 ml)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Aerosol Saline 4ml by inhalation for 5-10 minutes on 1 test day.
To be compared to Aerosol Furosemide (40mg) Arm and IV Furosemide Arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aerosol Saline (8 ml)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Aerosol Saline 8ml by inhalation for 5-10 minutes on 2 test days.
To be compared to Aerosol Furosemide (80mg) Arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Furosemide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Furosemide 15 mg diluted in 10 ml of saline by intravenous delivery for 5 minutes on 1 test day.
To be compared to Aerosol Furosemide (40mg) Arm and Aerosol Saline (4 ml) Arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <arm_group_label>Aerosol Furosemide (40 mg)</arm_group_label>
    <arm_group_label>Aerosol Furosemide (80mg)</arm_group_label>
    <arm_group_label>IV Furosemide</arm_group_label>
    <other_name>Lasix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <arm_group_label>Aerosol Saline (4 ml)</arm_group_label>
    <arm_group_label>Aerosol Saline (8 ml)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy

        Exclusion Criteria:

          -  Unstable heart or circulation disease

          -  Stroke

          -  Seizure disorder

          -  Severe migraine headaches

          -  Liver or kidney disease

          -  Adrenal gland problem (Pheochromocytoma)

          -  Nerve problems that may affect your breathing sensation

          -  Brain cancer

          -  Drug or alcohol problem

          -  Systemic lupus erythematosis (SLE)

          -  High levels of depression, panic disorder, or other significant mental health
             problems

          -  Serious ongoing pain

          -  Pregnant

          -  Under 18 years old

          -  Not Fluent in English
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert B Banzett, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Banzett RB, Adams L, O'Donnell CR, Gilman SA, Lansing RW, Schwartzstein RM. Using laboratory models to test treatment: morphine reduces dyspnea and hypercapnic ventilatory response. Am J Respir Crit Care Med. 2011 Oct 15;184(8):920-7. doi: 10.1164/rccm.201101-0005OC. Epub 2011 Jul 21.</citation>
    <PMID>21778294</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 6, 2017</lastchanged_date>
  <firstreceived_date>September 23, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Robert Banzett</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>dyspnea</keyword>
  <keyword>Laboratory model of dyspnea in healthy subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
